Faisal Khurshid
Stock Analyst at Leerink Partners
(4.29)
# 418
Out of 5,005 analysts
25
Total ratings
60%
Success rate
18.23%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $11.35 | +76.21% | 1 | Sep 25, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $64.83 | +12.60% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $2.35 | -14.89% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $99.02 | +3.01% | 2 | Jul 10, 2025 | |
| ABCL AbCellera Biologics | Assumes: Outperform | $5 | $5.90 | -15.25% | 1 | Jul 7, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $1.55 | -35.48% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $15.89 | +183.20% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $9.38 | +70.58% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.52 | +31.58% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $0.78 | +1,963.98% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 | $57.90 | +3.63% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $89.64 | -10.75% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $3.93 | +281.68% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $7 | $9.88 | -29.15% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $19.11 | +135.48% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $37.62 | -36.20% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.35 | +418.52% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $5.76 | +38.89% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.98 | +411.09% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $4.83 | +127.74% | 1 | Mar 21, 2023 |
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $11.35
Upside: +76.21%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $64.83
Upside: +12.60%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $2.35
Upside: -14.89%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $99.02
Upside: +3.01%
AbCellera Biologics
Jul 7, 2025
Assumes: Outperform
Price Target: $5
Current: $5.90
Upside: -15.25%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $1.55
Upside: -35.48%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $15.89
Upside: +183.20%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $9.38
Upside: +70.58%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.52
Upside: +31.58%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $0.78
Upside: +1,963.98%
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $57.90
Upside: +3.63%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $89.64
Upside: -10.75%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $3.93
Upside: +281.68%
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $9.88
Upside: -29.15%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $19.11
Upside: +135.48%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $37.62
Upside: -36.20%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.35
Upside: +418.52%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $5.76
Upside: +38.89%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.98
Upside: +411.09%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $4.83
Upside: +127.74%